FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2088264967> ?p ?o ?g. }

• W2088264967 endingPage "237" @default.
• W2088264967 startingPage "230" @default.
• W2088264967 abstract "Paclitaxel (Tx)-loaded anti-HER2 immunonanoparticles (NPs-Tx-HER) were prepared by the covalent coupling of humanized monoclonal anti-HER2 antibodies (trastuzumab, Herceptin ® ) to Tx-loaded poly ( dl -lactic acid) nanoparticles (NPs-Tx) for the active targeting of tumor cells that overexpress HER2 receptors. The physico-chemical properties of NPs-Tx-HER were compared to unloaded immunonanoparticles (NPs-HER) to assess the influence of the drug on anti-HER2 coupling to the NP surface. The immunoreactivity of sulfo-MBS activated anti-HER2 mAbs and the in vitro efficacy of NPs-Tx-HER were tested on SKOV-3 ovarian cancer cells that overexpress HER2 antigens. Tx-loaded nanoparticles (NPs-Tx) obtained by a salting-out method had a size of 171 ± 22 nm (P.I. = 0.1) and an encapsulation efficiency of about of 78 ± 10%, which corresponded to a drug loading of 7.8 ± 0.8% (w/w). NPs-Tx were then thiolated and conjugated to activated anti-HER2 mAbs to obtain immunonanoparticles of 237 ± 43 nm (P.I. = 0.2). The influence of the activation step on the immunoreactivity of the mAbs was tested on SKOV-3 cells using 125 I-radiolabeled mAbs, and the activity of the anti-HER2 mAbs was minimally affected after sulfo-MBS functionalization. Approximately 270 molecules of anti-HER2 mAbs were bound per nanoparticle. NPs-Tx-HER exhibited a zeta potential of 0.2 ± 0.1 mV. The physico-chemical properties of the Tx-loaded immunonanoparticles were very similar to unloaded immunonanoparticles, suggesting that the encapsulation of the drug did not influence the coupling of the mAbs to the NPs. No drug loss was observed during the preparation process. DSC analysis showed that encapsulated Tx is in an amorphous or disordered-crystalline phase. These results suggest that Tx is entrapped in the polymeric matrix and not adsorbed to the surface of the NPs. In vitro studies on SKOV-3 ovarian cancer cells demonstrated the greater cytotoxic effect of NPs-Tx-HER compared to other Tx formulations. The results showed that at 1 ng Tx/ml, the viability of cells incubated with drug encapsulated in NP-Tx-HER was lower (77.32 ± 5.48%) than the viability of cells incubated in NPs-Tx (97.4 ± 12%), immunonanoparticles coated with Mabthera ® , as irrelevant mAb (NPs-Tx-RIT) (93.8 ± 12%) or free drug (92.3 ± 9.3%)." @default.
• W2088264967 created "2016-06-24" @default.
• W2088264967 creator A5008423807 @default.
• W2088264967 creator A5013683035 @default.
• W2088264967 creator A5028842714 @default.
• W2088264967 creator A5069108772 @default.
• W2088264967 creator A5076375585 @default.
• W2088264967 creator A5086227940 @default.
• W2088264967 date "2009-10-01" @default.
• W2088264967 modified "2023-09-27" @default.
• W2088264967 title "Nanomedicines for active targeting: Physico-chemical characterization of paclitaxel-loaded anti-HER2 immunonanoparticles and in vitro functional studies on target cells" @default.
• W2088264967 cites W1512026049 @default.
• W2088264967 cites W1975842578 @default.
• W2088264967 cites W1983671192 @default.
• W2088264967 cites W1985744874 @default.
• W2088264967 cites W1999204999 @default.
• W2088264967 cites W1999813833 @default.
• W2088264967 cites W2002516695 @default.
• W2088264967 cites W2002980144 @default.
• W2088264967 cites W2004490932 @default.
• W2088264967 cites W2005293308 @default.
• W2088264967 cites W2013768689 @default.
• W2088264967 cites W2017865089 @default.
• W2088264967 cites W2018693859 @default.
• W2088264967 cites W2021249886 @default.
• W2088264967 cites W2023409962 @default.
• W2088264967 cites W2027929569 @default.
• W2088264967 cites W2030173263 @default.
• W2088264967 cites W2031104374 @default.
• W2088264967 cites W2033348480 @default.
• W2088264967 cites W2035423028 @default.
• W2088264967 cites W2038998098 @default.
• W2088264967 cites W2044647958 @default.
• W2088264967 cites W2045000096 @default.
• W2088264967 cites W2048827359 @default.
• W2088264967 cites W2056647735 @default.
• W2088264967 cites W2059877047 @default.
• W2088264967 cites W2065848180 @default.
• W2088264967 cites W2066354221 @default.
• W2088264967 cites W2074772243 @default.
• W2088264967 cites W2087020662 @default.
• W2088264967 cites W2087324070 @default.
• W2088264967 cites W2089773350 @default.
• W2088264967 cites W2094140369 @default.
• W2088264967 cites W2095156669 @default.
• W2088264967 cites W2095248480 @default.
• W2088264967 cites W2102449174 @default.
• W2088264967 cites W2108795463 @default.
• W2088264967 cites W2140250503 @default.
• W2088264967 cites W2152183134 @default.
• W2088264967 cites W2156368993 @default.
• W2088264967 cites W2156969927 @default.
• W2088264967 cites W2160314751 @default.
• W2088264967 cites W2172105255 @default.
• W2088264967 cites W2318605753 @default.
• W2088264967 doi "https://doi.org/10.1016/j.ejps.2009.07.006" @default.
• W2088264967 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19632322" @default.
• W2088264967 hasPublicationYear "2009" @default.
• W2088264967 type Work @default.
• W2088264967 sameAs 2088264967 @default.
• W2088264967 citedByCount "60" @default.
• W2088264967 countsByYear W20882649672012 @default.
• W2088264967 countsByYear W20882649672013 @default.
• W2088264967 countsByYear W20882649672014 @default.
• W2088264967 countsByYear W20882649672015 @default.
• W2088264967 countsByYear W20882649672016 @default.
• W2088264967 countsByYear W20882649672017 @default.
• W2088264967 countsByYear W20882649672018 @default.
• W2088264967 countsByYear W20882649672019 @default.
• W2088264967 countsByYear W20882649672020 @default.
• W2088264967 countsByYear W20882649672021 @default.
• W2088264967 countsByYear W20882649672022 @default.
• W2088264967 countsByYear W20882649672023 @default.
• W2088264967 crossrefType "journal-article" @default.
• W2088264967 hasAuthorship W2088264967A5008423807 @default.
• W2088264967 hasAuthorship W2088264967A5013683035 @default.
• W2088264967 hasAuthorship W2088264967A5028842714 @default.
• W2088264967 hasAuthorship W2088264967A5069108772 @default.
• W2088264967 hasAuthorship W2088264967A5076375585 @default.
• W2088264967 hasAuthorship W2088264967A5086227940 @default.
• W2088264967 hasConcept C112613896 @default.
• W2088264967 hasConcept C121608353 @default.
• W2088264967 hasConcept C12554922 @default.
• W2088264967 hasConcept C126322002 @default.
• W2088264967 hasConcept C13965031 @default.
• W2088264967 hasConcept C155672457 @default.
• W2088264967 hasConcept C159654299 @default.
• W2088264967 hasConcept C171250308 @default.
• W2088264967 hasConcept C178790620 @default.
• W2088264967 hasConcept C185592680 @default.
• W2088264967 hasConcept C192562407 @default.
• W2088264967 hasConcept C202751555 @default.
• W2088264967 hasConcept C203014093 @default.
• W2088264967 hasConcept C2777292972 @default.
• W2088264967 hasConcept C2777366897 @default.
• W2088264967 hasConcept C2779786085 @default.
• W2088264967 hasConcept C521977710 @default.
• W2088264967 hasConcept C530470458 @default.

• next